Tech transfer offices are under increasing pressure to generate revenue, but an innovative tech transfer strategy can help them deliver.
Tech transfer offices are still defined by major licensing blockbusters – for example Northwestern’s royalties from epilepsy drug Lyrica or Columbia’s Axel patents, which cover a method of introducing foreign proteins into nucleated cells – but the field is taking on new dimensions as universities increasingly see those offices as critical revenue drivers. As a result, the future looks more dynamic, sustainable and exciting for all involved.
While the traditional focus of tech transfer offices has been to…
